In agreement with data presented in our previous study [9], serglycin was expressed in minute levels in low aggressive MDA-MB-468 and MCF-7 cells, whereas it was expressed in elevated levels in high aggressive MDA-MD-231 breast cancer cells, which are KRAS38G→A and BRAF1391G→T mutant (Figure 1(a)) [13, 14]. This evidence concerns the gene SRGN and breast carcinoma.